Trial Profile
A Single-arm, Open Phase II Clinical Trial of Anti-PD-1 Antibody SHR-1210 Combined With Nimotuzumab as Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Nimotuzumab (Primary)
- Indications Cancer metastases; Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Jul 2021 Planned End Date changed from 1 Jan 2023 to 1 Sep 2023.
- 06 Jul 2021 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2022.
- 06 Jul 2021 Planned initiation date changed from 1 Jan 2021 to 1 Sep 2021.